Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder

Mené sur des patients atteints d'un cancer et souffrant de troubles dépressifs sévères, cet essai non randomisé évalue l'intérêt de la psilocybine (un hallucinogène, agoniste au niveau du récepteur 5-HT2A) pour traiter leur dépression

Résumé en anglais

About 15% of patients with cancer experience major depression, which is associated with lower treatment adherence and reduced quality of life. Yet, oncologists often feel inadequate to address mental health issues, and many treatments have limited success in treating depression.Psilocybin is a 5-HT2A receptor agonist with success in reducing a variety of psychiatric symptoms while using 2 therapists per patient. To create a scalable, rapidly effective depression treatment, this nonrandomized controlled trial administered psilocybin in a 1-to-1 therapist-to-patient ratio to groups of patients with cancer who were diagnosed with major depression disorder in a community cancer center.